FACTOR VIII:Ca CHROMOGENIC ASSAY

Abstract: A chromogenic assay for determination of blood coagulation Factor VIII:Ca, using an indicator of Factor Xa simultaneously as a mesure of Factor VIII:Ca concentration and as an inhibitor of Factor Xa. This technique can be applied to measure the concentration of an activating enzyme using the rate of conversion of the indicator molecule of the product of that enzyme as an indirect indicator of enzyme concentration.

Description: FACTOR Vlll.Ca CH CMOGEKIC ASSAY Field of the Invention This application is a σαntinuation-in-part of application serial number 7/394,822 filed August 17, 1989. This invention relates generally to the field of chrαnogenic assays and more specifically to a chromogenic -assay for the determination of levels of the blood coagulation factor VIII:Ca contained in plasma. Background of the Invention Clot formation in plasma is initiated by the serial enzymatic activation of clotting factors, which results in the appearance of small traces of thrcrribin. Hurlet-Birk Jensen A., et al. Factor V and VIII Activation "In Vivo" During Bleeding. Evidence of Thrcrribin Formation at the Early Stage of Hecπostasis. Path. Biol . 1976; 24, p.6-10. The explosive nature of the coagulation process is a consequence of the position feedback reactions that these thrcrribin traces exert on the co actors V. Colman, FW, The Effect of Proteolytic Enzymes on Bovine Factor VI. Kinetics of Activation and Inactivation by Bovine Thrcπibir.. Biochem. 1969; 4: p.1438- 1444, Lindho t, MJ, Activation of Bovine Factor V by Thrcrribin and a Protease from Russell's Viper Venom (RW) , Thrαrib. Hae ost. 1979; 42: p.491. Rapaport, SI, et al., Further .Evidence That Thrcrribin Activation of Factor VIII is an Essential Step In Intrinsic Clotting, Scand J. Clin. Lab. Invest.1965; 17: p.84-88, Biggs, R. , et al. Thrcrribin and the Interaction of Factors VIII and IX, Brit J. Haemat. 1965; 11: p.276-295, Hβrker, HC, et al., Reaction Sequence of Blood Coagulation, Nature 1967; 215: p.1201, Osterud, B. , et al.. Formation of Intrinsic Factor X Activator With Special Reference to the Role of Thrcrribin, Br. J. Hae atol 1971; 21: p.643- 660, Hultin, MB, et al., Activation of Factor X by Factors IXa and VIII: A Specific Assay for Factor IXa in the Presence of Thrcrribin- Activated Factor VIII, Blood 1978; 52: p.928-940, and on platelets, Davey, MG, et al . , Actions of Thrcrribin and Other Proteolytic Enzymes o Blood Platelets. Nature 1967; 216: p.857-858. Activated Factors V and VIII:C dramatically boost the performance of Factors Xa and IXa, whereas activated platelets provide, among other things, the negatively charged surface necessary for most coagulation reactions. Bevers, EM, et al., Generation of Prothrombin Converting Activity and the Exposure of Phosphatidylserine at the Outer Stirface of Platelets, Eur. J. Bioch. 1982; 122: p.429-436. According to prior methods Factor VIII:C concentrations, and also Factor VIII:C activation in plasma were measured using coagulation assays, involving VIII:C deficient plasma. Soulier, p. , et al. , Deficit En Berne Facteur Prothroriboplastigue plasmatique. Rapports Eatre le PTA et le Facteur Hage an, Thro bin. Diathes. Haemorrh. 1958; 2: p.l, Rappaport, SI, et al., A Simple Specific One-Staqe Assay for Plasma Thrcrriboplastir. Antecedent Activity. J. Lab. Clin. Med. 1961; 57: p.771, Hardisty, RM, et al., A One-Staqe Factor VIII (Antihemophilic Globulin) Assay and Its uses on Venous and Capillary Plasma. Throπibos. Diathes. Haemorrh. 1962; 7: p.215, Veltkaπp, JJ, et al., Detection of the Carrier State ± Hereditary Coagulation Disorders. Thro bos. Diathes. Haemorrh. 1968; 19: p.279-303 and 403-422, Suomsla, E, et al. The Activation of Factor X Evaluated by Using Synthetic Substrates, Thromb. Res. 1977; 1: p.267-281, Van Dieijen, G, et al., The Role of Phospholipid and Factor Villa in the Activation of Bovine Factor X, J. Biol. Chem. 1981; 256: p. 3433-3442. The occurrence of various feedback reactions, however, made it impossible to relate, in a quantitatively reliable way, these values to the amounts of activated VIII:Ca. The advent of a chrcrnoge ic substrate for Factor Xa, and the recognition that a property of activated Factor VIII:C is accelerated activation of Factor X by IXa, phospholipids and calcium ions made a more direct method of determining functional Factor VIII:Ca conceivable. Suomela, H, et al . Supra, Van Dieijen, et al., The Role of Phospholipid and Factor Villa in the Activation of Bovine Factor X, J. Biol. Chem. 1981; 256: p.3433-3442. Still, feedback reactions of Factor Xa on Factor VIII:C, and the inactivation of Factor Xa by the antithrcrribin III and <-x.1-antitrypsin present in plasma, threatened to seriously hamper the feasibility of such a .Factor VIII:Ca assay in plasma. Vehar, GA, et al., Preparation and Properties of Bovine Factor VIII (Antihemophilic Factor), Biochemistry 1980; 19: p.401-410, Hultin, MB, Role of Human Factor VIII in Factor X Activation, J. Clin. Invest. 1982; 69: p.950-955, Lollar, P, et al., Activation of Porcine Factor VIII:Cby Thrcrribin and Factor Xa. Biochemistry 1985; 24: p.8056-8064, Neuenschwanter, P, et al., A Comparison of Phospholipid and Platelets in the Activation of Hunan Factor VIII by Thrombin and Factor Xa, and in the Activation of Factor X, Blood 1988; 72: p.1761-1770, and Factor X, Jesty, J., et al., The Mechanism of Activation of Factor X, J. Biol. Cherr.. 1974; 249: p.5614-5622. On the basis of a methodby Pieters et al., In Situ Generated Throrribin is the Only Enzyme that Effectively Activates Factor VIII:C and Factor V in Plasma, Blood, in press (hereby incorporated by reference), we developed a scheme for measuring Factor VIII:Ca in plasma, that circumvents these difficulties. The classical method for the determination of Factor VIII:Ca activity in plasma est.imates the activity of the clotting factor in a plasma sample from the amount of time by which it shortens the prolonged clotting time of a plasma congenitally deficient in that factor, as compared to a normal plasma. As there is no solid theoretical basis that underlies the relationship between the coagulationtime and the percentage of coagulation factor activity, these assays are bioassays in the sense that the activities have to be read frcrn a standard curve, and that the values of these activities are only valid with respect to the methodby which they aremeasured. Consequently, a need exists for a more quantitative method to measure Factor VIII:Ca. Suπr ary of the Invention This invention provides ahighly sensitive, reproducible, and convenient assay for determination of the levels of blood coagulation Factor VIII:Ca contained in blood serum, plasma, and other fluids. Since Factor VIII:Ca is not an enzyme, its functional concentration cannot .be measured directly by way of a chrcmogenic substrate. Instead, the ability of Factor VIII:Ca to enhance Factor X activation in the presence of Factor IXa, phospholipids, and - a^, is exploited. Factor Xa concentration can be determined chrcmogenically, which permits a quantitative estimation of the Factor VIII:Ca a level. In the assay of this invention, a test sample of blood serum, plasma, or other Factor VIII:Ca containing fluid is added to a solution containing activated blood coagulation Factor IXa, and calcium ions and phospholipid. Factor X is added to the mixture. Factor IXa and Factor VIII:Ca act to accelerate the conversion of the Factor X, a zymogen, to activated Factor X, (hereafter referred to as Factor Xa) . An indicator agent is added to the reaction mixture, which reacts with the Factor Xa so formed, to release a signal molecule, which may be conveniently measured. The following equations further illustrate the steps of the present method: Factor VIII:Ca 2) Factor X Factor IXa Factor Xa Phospholipid Ca* * 3) Indicator Agent Factor Xa signal molecule In accordance with the method of this invention, an assay is provided which has a high degree of sensitivity and reproducibility for Factor VIII:Ca concentration. Another object of this invention is to provide a kit for the convenient performance of routine laboratory assays of Factor VIII:Ca containing fluids. A further object of this invention is to provide an assay for Factor VIII:Ca which is not affected by the presence of heparin and other blood clot interactive substances. A still further object of this invention is to provide a bulk source of assay components to facilitate the operation of automated equipment capable of processing for assay large numbers of test samples. It is another object of this invention to suppress side reaction of Factor Xa that might distort the correlation. To that end it was found that inhibition of these side reactions can be obtained by using a high concentration of chromogenic substrate for Factor Xa. This assay methodology may be applicable to the measurement of other activated factors; in particular e.g. Factor V. An activating enzyme (Enzyme A, i.e. the Factor IXa - factor VIII:Ca - phospholipid complex), is measured by indirectly measuring the rate of activation of an enzyme that is its natural substrate. The enzyme that results from this activation (Enzyme E) is allowed to act iπmediately on an indicator molecule. By its reaction with the indicator molecule (the concentration of which must suffice tc saturate enzyme B) complicating reactions involving enzyme B are inhibited. (i.e. example, the activation of Factor VIII:C by Factor Xa, and the inhibition of Factor Xa by antithrcrribin III). Because enzyme E increases linearly in time, the signal molecule is produced according to a parabolic curve. The slope of the first derivative of this parabola is proportional to the concentration of enzyme A. The advantages and performance of the present invention will be better understood by reference to the following detailed description and Example. Detailed Description of the Preferred Embodiment The method of the assay of the present invention comprises the steps of: 1. Combining a sample and a solution containing a sufficient amount of Factor IXa to saturate substantially all Factor VIII:Ca in said sample; a sufficient amount of a thrombin inhibitor to inhibit thrombin activity without affecting FactorXa activity, a sufficient amount of phospholipids, calcium ion to facilitate the conversion of Factor X to Factor .Xa. 2. Adding to the mixture a sufficient amount of Factor X to saturate substantially all of the corrplex of ac or IXa, Factor VII :Ca and phospholipid. 3. .Adding to the mixture a sufficient amount of an indicator agent capable of reacting with Factor Xa, said quantity of indicator agent being sufficient to suppress Factor Xa side reactions, to release a signal molecule; and 4. Measuring the signal molecule. The foregoing method may be exemplified by reference to the following equations: Factor VIII:Ca 1) Factor X Factor IXa v, Factor Xε Phospholipid Ca 2) Indicator Agent Factor Xa >, signal molecule In practicing the method of the present invention, Factors IX and X may be obtained frσrr. virtually any animal or human source, and may be prepared by any fracticnation or concentration method known to the art. In addition, a highly purified source of such factors is from recσrribinant vectors propagated in suitable host cell lines. One advantage to using factors from animal or recombinant vector sources is assurance that the product factors will not be contaminated with human pathogens such as hepatitis A and B, HTLV-III, or other such viruses. In the preferred embodiment of the present method, blood coagulation factors are of bovine origin. It should be noted that because the sample undergoes a considerable dilution in the assay mi.xture (30 to 100 fold), the endogenous Factor IX concentration will very probably not be high enough to saturate all Factor VIII:Ca (up to 1 U/ml) present in the sample on Factor IXa, which is necessary for a reliable assay. Thus, a sufficient amount of Factor IXa must be added. The conversion of Factor X to Xa proceeds most efficiently in the presence of phospholipids. These phospholipids may bε such representative compounds as phosphotidyl choline, phosphotidyl serine, or cholesterol and mixtures thereof in various proportions. Other lipid and phospholipid compositions may be substituted as well. It is our experience that optimal results are obtained with vesicles of 20 mole-% phosphatidyl serine and 80 mole-% phosphatidyl choline. This is not critical however; the ranges of acceptable composition are 5 to 40 mole-% phosphatidyl serine, 1 to 20 mole-% cholesterol, .and 50-90 mole-% of phosphotidyl choline. Any chemical source of calcium cation may be used to effectuate the conversion of Factor X. Sufficient calcium ion may be added to the original incubation mixture to drive the reaction converting Factor X to Factor Xa, or a second amount of calcium ion may be added at the time Factor X is to be converted. While the source of calcium cation (Ca " ) may be CaCl-, Ca NC^, CaSC^, or other inorganic calcium cation containing compounds, the preferred source is CaCl-. A thrcrribin inhibitor is used to block thrcrribin activity on chrcmogenic substrate for Factor Xa. Useful thrombin inhibitors include -NRPA? and hirudin. In performing the assay of this invention, great variations in protein concentrations, incubation times, reagent concen¬ trations, and temperatures may be employed. The selection of particular assay parameters will be influenced by the source, type, and size of the sample to be assayed, the anticipated levels of Factor VIII:Ca contained therein, and the threshold of sensitivity desired. Tal jig these circumstances into account, selection of assay parameters will be apparent to those skilled in the art. The parameters of the assay, which will enable anyone skilled in the art to carry out the assay in accordance with a preferred embodiment are set forth in the Example which follows. It should be noted that, although the rate of Factor X activation is linearly proportional to the level of Factor VIII:Ca, the rate of amidolysis of the chrcmogenic substrate is not. In fact, the relation between absorbance and Factor VIII:Ca concentration is a second order polynomial. Because of t.his, at least two points are needed for a determination of the Factor VIII:Ca concentration. We found that best results are obtained when absorbance is measured continuously in time. The resulting curve is then analyzed by way of a second order least squares fit procedure. This yields the parameters A, B and C (equation: A + B.t + C.t 2 ). C is proportional to Factor VIII:Ca concentration. Accordingly, an optional additional step in the present assay consists of adding a quenching agent to the incubation mixture at a fixed point in time after ccrtmence ent of the reaction converting Factor X to Factor Xa. The quenching ccmposition may be any substance capable of disrupting a protein-mediated chemical reaction, but the preferred composition is a buffered solution comprised of Tris, ethylenediaminetetracetic acid, sodium chloride, and sodium azide. The blood coagulation factors of the present assay and the Factor VIII:Ca protein to be assayed are fragile functional proteins, and desirably a stabilizing substance or substances may be included during the incubation to optimize assay conditions and to protect functionality of assay components. Such stabilizing substances also protect functionality during storage wherein the assay components are maint-ained in either a wet or lyophiiized state. Various stabilizers are known in the art; the preferred substances being polyethylene glycol and bovine serum albumin, either singly or in combination. The indicator agent of the present invention is a molecule capable of reacting with blood coagulation Factor Xa. In such reaction, by-products of chemical reaction must be generated which produce a measurable signal moiety, U.S. Patent Nos. 4,480,030 and 4,666,831 describe a class of chrcmogenic compounds capable of reacting with Factor Xa. The indicator CH QO0-D-CHG-Gly-.Arg-pNA- AcOΞ (Pentapharm, Basel, Switzerland), is preferred. Upon reaction with Factor .Xa, a signal molecule P-nitroaniline is released, which maybe conveniently measuredby spectrophotometric determination at 405nm. Other chrcmogenic indicator agents which are applicable with the present invention are available alsc. From the preceding disclosure it will be apparent to those skilled in the art that the signal moiety of the target indicator agent may be radiolabelled, preferably by tritium or carbon 14, and the signal molecule upon release can be isolated by exclusion chrcmatography, dialysis, iπrπunoadsorption, or other convenient separation techniques. Radiolabelled indicator agents, while more curberscme to use, have the advantage of greater sensitivity in those situations wherein unusually great sensitivity is needed. It is contemplated within the scope of the present invention that the components of the Factor VIII:Ca assay may be available as a kit for the convenient and routine performance of a large number of such assays. A kit for performing a Factor VIII:C assay on a sample comprising: a) a first vessel containing: a sufficient amount of Factor IXa to saturate all Factor VIII:Ca in said sample, a sufficient amount of a thrombin inhibitor to inhibit thrcrribin activity without affecting Factor Xa activity, a sufficient amount of phospholipid and calcium ion to facilitate the conversion of Factor X to Factor Xa; b) a second vessel con a^.ng a sufficient .amount of Factor X to saturate the ccrηplex of Factors IXa and VIII:C and phospholipid; c) a third vessel cont-aining a sufficient quantity of an indicator agent capable of reacting with Factor Xa, said quantity of indicator agent being sufficient to suppress Factor Xa side reactions. Rn. optimal fourth vessel can be included with a quenching composition. To optimize shelf life of the components of the kit it is desirable to lyophilize them in the aforementioned vessels. The said components may be readily reconstituted by adding water at the time assays are to be performed. The vessels containing assay components are readily adapted to automated assay equipment. EXAMPLE 1. FACTOR VIII:Ca GENERATION IN THRGMBOPIASTIN ACTIVATED PLASMA Factor VIII:Ca generation is triggered by addition of 10 μl of a solution of CaCl, (167 nrM) containing human brain thromboplastin (dilution 1/18) to 90 μl of defibrinated plasma. At various times aliquots of this mixture are taken for assay of the Factor VIII:Ca concentration. Each aliquot is diluted 100 fold in a cuvette containing Factor IXa (100 nM), phospholipid vesicles (20 μM, 20 mole-% phosphatidyl serine/80 mole-% phosphatidyl choline), CaCl, (5 M) and -NaPAP (1 μM), in buffer at 37°C. After 10 seconds, Factor .Xa chrαmogenic substrate (CH j OCO-D-CHG-Gly-aArg-Pna- AcOH; Pentapharm, Basel Switzerl-and) is added to the cuvette so as to obtain a concentration of 400 μM. Factor X activation is started after another 10 seconds by addition of Factor X, to a concentration of 0.33 μM. Concentrations mentioned are final, i.e. they are obtained after all additions to the cuvette have been made. The course of absorbance at 405 nm is then measured continuously in time. The build up of absorbance in time is governed by the following equation: A(t).= AΛ + kl • + k2 • [VIII:Ca] . t The quadratic termwhich is a function of the Factor VIII:Ca concentration is estimated frcrn the absorbance-t.ime curve by way of a quadratic least squares fit procedure. From this the Factor VIII:Ca concentration is inferred, using a value for k2 of 1.164 mA/minV%VIII:ca, which has been determined previously. Factor VIII:Ca concentrations at each time point, stated as a percentage of the total Factor VIII:C, are shown in the table below. TRBLE 1 Time (mis) [VIII:Ca] (%) 0.50 0.7 1.00 2.9 1.25 10.1 1.50 44.1 1.75 73.8 2.0C 62.1 2.25 49.7 2.75 39.8

Claims: What is claimed is: 1. A kit for performing a Factor VIII:Ca assay an a sample comprising: a) a first vessel containing: a sufficient .amount of Factor IXa to saturate all Factor VIII:Ca in said sample, a sufficient -amount of a thrcrribin inhibitor to inhibit thrcrribin activity without affecting Factor Xa activity, a sufficient amount of phospholipid and calcium ion to facilitate the conversion of Factor X to Factor Xa; b) a second vessel containing a sufficient amount of Factor X to saturate the complex of Factors IXa and VIII:Ca and phospholipid; and c) a third vessel containing a sufficient quantity of an indicator agent capable of reacting with Factor Xa, said quantity of indicator agent being sufficient to suppress Factor Xa side reactions. 2. The kit of Claim 1 where Factors IXa and X are of bovine origin. 3. The kit of Claim 1 wherein the phospholipid is comprised of: between 5 to 40 mole-% phosphatidyl serine, 0 to 20 moie-% cholesterol and 50-90 mole-% of phosphotidyl choline. 4. The kit of Claim 1 wherein the phospholipid is coπprised of 20 mole-% of phosphatidyl serine and 80 mole-% phosphatidyl choline. 5. The kit of Claim 1 wherein the said indicator is selected from the class consisting of: enzymatic, radicmetric, fluorescent or chromogenic indicators. 6. The kit of Claim 1 wherein said indicator is chrcmogenic. 7. A kit for performing a Factor VIII:Ca assay on a sample comprising: a) a first vessel containing: a sufficient amount of Factor IXa to saturate all Factor VIII:Ca in said sample, a sufficient amount of a thrombin inhibitor to inhibit thrombin activity without affecting Factor Xa activity, a sufficient amount of phospholipid and calcium ion to facilitate the conversion of Factor X to Factor Xa; b) a second vessel containing a sufficient amount of Factor X to saturate the complex of Factors IXa and VIII:Ca and phospholipid; c) a third vessel containing a sufficient quantity cf quenching agent to stop the conversion of Factor X to Factor Xa; and d) a fourth vessel containing a sufficient quantity of an indicator agent capable of reacting with Factor Xa, said quantity of indicator agent being sufficient to suppress Factor Xa side reactions. s. The kit of Claim 7 where Factors IXa and X are of bovine origin. 9. The kit of Claim 7 wherein the phospholipid is comprised of: between 5 to 40 mole-% phosphatidyl serine, 0 to 20 mole-% cholesterol and 50-90 mole-% of phosphotidyl choline. 10. The kit of Claim 7 wherein the phospholipid is comprised of 20 mole-% of phosphatidyl serine and 80 mole-% phosphatidyl choline. 11. The kit of Claim 7 wherein the said indicator is selected from the class consisting of: enzymatic, radicmetric, fluorescent or chrcmogenic indicators. 12. The kit of Claim 7 wherein said indicator is chrcmogenic. 13. The kit of Claim 7 wherein said quenching agent is any substance capable of dis.rupting a protein-mediated chemical reaction. 14. The kit of Claim 13 wherein the quenching substance is a buffered solution of Tris, ethylenediaminetetracetic acid, sodium chloride and sodium azide. 15. A method for determining the concentration of blood coagulation Factor VIII:Ca in a fluid sample comprising: a) combining into a mixture said fluid sample with a sufficient amount of Factor IXa to saturate substantially all Factor VIII:Ca in said sample; a sufficient amount cf thrombin inhibitor tc inhibit thrombin activity without affecting Factor Xa activity in the presence cf a sufficient amount cf calcium ions and phospholipids to facilitate the conversion of Factor X to Factor Xa; b) adding a su ficient amount of Factor X to saturate the complex of Factors IXa and VIII:Ca and phospholipid; c) adding a suficient quantity of an indicator agent capable of reacting with .Factor Xa, whereby to release a signal molecule said quantity of indicator agent being sufficient to suppress Factor Xa side reactions: and d) measuring the signal mole ule. 16. The method of Claim 15, together with the further step cf adding a quenching substance at a fixed point in time after the addition of Factor X to prevent the conversion of Factor X to Factor Xa. 17. The method cf Claims 15 and 16 wherein Factors IXa and X are obtained from an a inal source. 18. The method of Claim 15 wherein Factors IXa and X are obtained from a reccmbinant vector propagated in a host cell line. 19. The method of Claim 15 wherein the indicator agent is selected from the class consisting of enzymatic, radicmetric, fluorescent or chrcmogenic indicators. 20. The method of Claim 15 wherein said indicator is chrcmogenic. 21. The method of Claim 20 wherein said indicator is CH OCO-D- CHG-Gly-Arg-Pna-AcOH. 22. A method for indirectly determining the concentration of blood coagulation enzyme wherein the substrate for said enzyme is the zymogen of a second enzyme in a fluid sample comprising: said blood coagulation enzyme, said zymogen of a second enzyme, and an indicator agent for said second enzyme in sufficient quantities to block all reactions of said second enzyme other than liberating a signal molecule from said indicator agent.

Inventors: BEGUIN SUZETTE LUCETTE, HEMKER HENDRIK COENRAAD, KESSELS HENDRICUS JOHANNES, BEGUIN, SUZETTE, LUCETTE, HEMKER, HENDRIK, COENRAAD, KESSELS, HENDRICUS, JOHANNES
Applicants: BAXTER DIAGNOSTICS INC, BAXTER DIAGNOSTICS INC.
Application year: 1991
Main classification: C12Q1
IPC codes: C12Q1, G01N33